Pyxis Oncology Income Statement (2020-2025) | PYXS

Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter)
16.15M2.82M11.04M
Cost of Revenue (Quarter)
0.47M2.39M
Gross Profit (Quarter)
15.67M2.82M8.65M
Operating items
Amortization - Intangibles (Quarter)
0.61M1.26M1.48M1.44M1.29M1.64M1.65M1.53M1.16M0.90M0.53M0.38M
Research & Development (Quarter)
32.77M3.21M7.85M7.23M20.07M17.17M19.03M29.85M11.90M11.39M14.69M11.61M13.03M13.95M17.74M14.02M17.04M17.13M17.81M21.71M
Selling, General & Administrative (Quarter)
2.96M2.74M3.77M9.20M11.32M8.56M9.36M8.12M9.05M6.73M10.67M6.16M8.25M6.08M6.01M5.08M5.87M5.44M5.65M5.23M
Other Operating Expenses (Quarter)
-36.17M-42.95M-29.31M172.18M0.47M20.96M2.39M
Operating Expenses (Quarter)
35.73M5.94M11.62M16.43M31.39M25.73M28.39M37.97M20.95M18.12M25.35M17.77M21.75M20.03M23.75M40.07M22.91M22.57M23.46M29.33M
Operating Income (Quarter)
-35.73M-5.94M-11.62M-16.43M-31.39M-25.73M-28.39M-37.97M-20.95M-18.12M-25.35M-17.77M-5.61M-20.03M-23.75M-40.07M-22.91M-19.75M-23.46M-18.30M
EBIT (Quarter)
-35.73M-5.94M-11.62M-16.43M-31.39M-25.73M-28.39M-37.97M-20.95M-18.12M-25.35M-17.77M-5.61M-20.03M-23.75M-40.07M-22.91M-19.75M-23.46M-18.30M
Non-operating items
Non Operating Investment Income (Quarter)
0.70M-0.78M-0.02M0.17M-0.12M-0.04M0.45M-0.18M-0.12M-0.05M0.07M-0.02M
Interest & Investment Income (Quarter)
0.00M0.01M0.01M0.01M0.01M0.16M0.72M1.87M1.07M1.66M1.71M1.59M0.26M0.39M1.80M0.09M1.24M0.99M0.80M0.59M
Other Non Operating Income (Quarter)
-1.10M-2.16M-2.56M-0.41M
Non Operating Income (Quarter)
-1.10M-1.97M-2.55M-0.40M0.01M0.16M0.72M1.87M1.71M2.22M2.31M2.17M2.35M2.73M2.55M2.33M1.76M1.68M1.46M1.29M
Net income details
EBT (Quarter)
-35.73M-5.93M-11.62M-16.42M-31.38M-25.56M-27.67M-36.10M-19.89M-16.46M-23.65M-16.17M-5.34M-17.30M-21.20M-37.73M-21.67M-18.07M-22.00M-17.00M
Tax Provisions (Quarter)
-2.16M1.12M
Profit After Tax (Quarter)
-36.83M-8.15M-14.18M-16.90M-31.38M-25.56M-27.67M-36.12M-19.24M-15.90M-23.05M-15.60M-3.26M-17.30M-21.20M-35.53M-21.16M-18.35M-22.00M-18.10M
Equity Income (Quarter)
-0.23M
Income from Continuing Operations (Quarter)
-35.73M-5.93M-11.62M-16.42M-31.38M-25.56M-27.67M-36.10M-19.89M-16.46M-23.65M-16.17M-5.34M-17.30M-21.20M-35.57M-21.67M-18.07M-22.00M-18.12M
Consolidated Net Income (Quarter)
-35.73M-5.93M-11.62M-16.42M-31.38M-25.56M-27.67M-36.10M-19.89M-16.46M-23.65M-16.17M-5.34M-17.30M-21.20M-35.57M-21.67M-18.07M-22.00M-18.12M
Income towards Parent Company (Quarter)
-35.73M-5.93M-11.62M-16.42M-31.38M-25.56M-27.67M-36.10M-19.89M-16.46M-23.65M-16.17M-5.34M-17.30M-21.20M-35.57M-21.67M-18.07M-22.00M-18.12M
Net Income towards Common Stockholders (Quarter)
-35.73M-5.93M-11.62M-16.42M-31.38M-25.56M-27.67M-36.10M-19.89M-16.46M-23.65M-16.17M-5.34M-17.30M-21.20M-35.57M-21.67M-18.07M-22.00M-18.12M
Additional items
EPS (Basic) (Quarter)
-27.26-5.54-8.9631.32-0.97-0.79-0.85-1.04-0.54-0.41-0.56-0.33-0.06-0.29-0.35-0.59-0.35-0.30-0.35-0.29
EPS (Weighted Average and Diluted) (Quarter)
-5.54-8.9631.32-0.97-0.79-0.85-1.04-0.54-0.41-0.56-0.33-0.06-0.29-0.35-0.59-0.35-0.30-0.35-0.29
Shares Outstanding (Weighted Average) (Quarter)
1.35M1.47M1.47M8.49M32.32M32.38M32.44M33.03M35.35M38.39M41.33M39.90M1.61M1.61M1.61M58.45M61.05M61.49M0.64M62.14M
Shares Outstanding (Diluted Average) (Quarter)
1.47M1.58M8.49M32.32M32.38M32.56M33.03M35.35M36.88M41.33M39.90M51.29M60.50M60.72M58.45M61.05M61.49M62.56M62.14M
EBITDA (Quarter)
-35.73M-5.94M-11.62M-16.43M-31.38M-25.56M-27.67M-36.10M-18.55M-16.68M-23.07M-15.43M-3.38M-17.34M-20.75M-35.75M-21.28M-18.41M-21.93M-18.12M
Tax Rate (Quarter)
5.73%-6.57%